View : 83 Download: 0

A retrospective analysis for patients with HER2-positive gastric cancer who were treated with trastuzumab-based chemotherapy: In the perspectives of ethnicity and histology

Title
A retrospective analysis for patients with HER2-positive gastric cancer who were treated with trastuzumab-based chemotherapy: In the perspectives of ethnicity and histology
Authors
Yi J.H.Kang J.H.Hwang I.G.Ahn H.K.Baek H.J.Lee S.I.Lim D.H.Won Y.-W.Ji J.H.Kim H.S.Rha S.Y.Oh S.Y.Lee K.E.Lim T.Maeng C.H.Kim M.J.Kim S.T.Lee J.Park J.O.Park Y.S.Lim H.Y.Kang W.K.Park S.H.
Ewha Authors
이경은
SCOPUS Author ID
이경은scopus
Issue Date
2016
Journal Title
Cancer Research and Treatment
ISSN
1598-2998JCR Link
Citation
vol. 48, no. 2, pp. 553 - 560
Keywords
ErbB-2 receptorEthnic groupsHistologyStomach neoplasmsTrastuzumab
Publisher
Korean Cancer Association
Indexed
SCIE; SCOPUS; KCI WOS scopus
Abstract
Purpose While the Trastuzumab for Gastric Cancer (ToGA) trial demonstrated the efficacy and safety of trastuzumab-based chemotherapy in HER2-positive metastatic gastric cancer, the overall survival (OS) benefit was not found in Asian and diffuse-type cancer patients. The aim of the study is to investigate predictive markers for trastuzumab-based chemotherapy. Materials and Methods Data of patients with HER2-positive gastric cancer treated with trastuzumab-based chemotherapy were analyzed retrospectively. Results A total of 168 Asian patients were included. The median age was 60 years (range, 27 to 85 years) and the male:female ratio was 118 (70.2%):50 (29.8%). Fourteen (8.3%), 63 (37.5%), 75 (44.6%), and 11 (6.5%) patients had well, moderately, poorly-differentiated tubular adenocarcinoma and signet ring cell carcinoma, respectively. With 14 complete responses and 73 partial responses, the response rate was 50.6%. The median progression-free survival (PFS) was 10.2 months (95% confidence interval [CI], 8.7 to 11.7), and the median OS was 18.5 months (95% CI, 16.4 to 50.6). Next, we investigated the effect of poorly-differentiated histology (PDH, poorly-differentiated tubular adenocarcinoma+signet ring cell carcinoma) on clinical outcomes. The median PFS (8.9 months vs. 11.5 months, p=0.16) was slightly inferior in PDH patients, and the median OS was significantly shorter in PDH patients (14.6 months vs. 19.0 months, p=0.025). Conclusion While subset analysis of the ToGA trial demonstrated that trastuzumab-based chemotherapy may not be beneficial for Asians and patients with PDH, our data may suggest that even in Asian patients and patients with PDH, trastuzumab-based chemotherapy could be associated with improved clinical outcomes in patients with HER2-positive gastric cancer. © 2016 by the Korean Cancer Association.
DOI
10.4143/crt.2015.155
Appears in Collections:
의과대학 > 의학과 > Journal papers
Files in This Item:
There are no files associated with this item.
Export
RIS (EndNote)
XLS (Excel)
XML


qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

BROWSE